Chemomab Therapeutics Ltd.

22.06-1.86-7.78%Vol 531.54K1Y Perf -9.16%
Jun 14th, 2021 16:00 DELAYED
BID22.00 ASK22.50
Open23.36 Previous Close23.92
Pre-Market- After-Market-
 - -  - -%
Target Price
43.50 
Analyst Rating
— — 0.00
Potential %
97.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap236.00M 
Earnings Rating
Price Range Ratio 52W %
6.22 
Earnings Date
13th May 2021

Today's Price Range

21.0923.69

52W Range

12.32168.80

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
10.36%
1 Month
29.76%
3 Months
-69.16%
6 Months
-52.13%
1 Year
-9.16%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CMMB22.06-1.8600-7.78
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.43-0.2248.84
Q04 2020-8.00-4.0050.00
Q03 2020-7.20-5.6022.22
Q02 2020-8.80-7.2018.18
Q01 2020-8.80-6.5625.45
Q04 2019-2.0831.841.63K
Q03 2019-0.15-2.26-1 406.67
Q02 2019-0.78-0.0593.59
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.43
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume531.54K
Shares Outstanding10.70M
Trades Count5.45K
Dollar Volume0
Avg. Volume270.02K
Avg. Weekly Volume1.15M
Avg. Monthly Volume520.71K
Avg. Quarterly Volume346.95K

Chemomab Therapeutics Ltd. (NASDAQ: CMMB) stock closed at 22.06 per share at the end of the most recent trading day (a -7.78% change compared to the prior day closing price) with a volume of 540.33K shares and market capitalization of 236.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Chemomab Therapeutics Ltd. CEO is Neil Cohen.

The one-year performance of Chemomab Therapeutics Ltd. stock is -9.16%, while year-to-date (YTD) performance is -20.3%. CMMB stock has a five-year performance of %. Its 52-week range is between 12.32 and 168.8, which gives CMMB stock a 52-week price range ratio of 6.22%

Chemomab Therapeutics Ltd. currently has a PE ratio of -108.70, a price-to-book (PB) ratio of 3.23, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -2.83%, a ROC of -3.07% and a ROE of -3.09%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Chemomab Therapeutics Ltd., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Chemomab Therapeutics Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Chemomab Therapeutics Ltd. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Chemomab Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Chemomab Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Chemomab Therapeutics Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.68, ATR14 : 3.18, CCI20 : 284.38, Chaikin Money Flow : -0.24, MACD : -1.02, Money Flow Index : 91.41, ROC : 48.85, RSI : 54.04, STOCH (14,3) : 68.60, STOCH RSI : 1.00, UO : 43.42, Williams %R : -31.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Chemomab Therapeutics Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a pivotal-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel therapeutics for fibrosis-related diseases.

CEO: Neil Cohen

Telephone: +972 25486555

Address: Kiryat Atidim, Building 7, Tel Aviv 6158002, , IL

Number of employees: 3

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits